FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115131296> ?p ?o ?g. }

• W2115131296 endingPage "A141" @default.
• W2115131296 startingPage "A141.1" @default.
• W2115131296 abstract "Introduction Midazolam is a short acting benzodiazepine that is commonly used for sedation during colonoscopy. There is no standard dose of midazolam, however, British Society of Gastroenterology guidelines suggest a maximum of 5 mg with lower doses for elderly patients. Bowel preparation and endoscopist are factors that have been clearly associated with improved polyp detection during colonoscopy. Anecdotally, colonoscopy in patients who are extremely agitated limits views and leads to a more difficult procedure. Data exploring the relationship between midazolam dose and ability to detect colonic polyps is limited. Methods A retrospective cohort study of all patients who had undergone colonoscopy at Milton Keynes General hospital between January 2010 and December 2012. Patients were identified from the Endoscopy Unit database and their records were reviewed. Patient details, midazolam dose and diagnosis on colonoscopy were extracted into a standardised form. Results 6200 patients were included for analysis. The median age was 62 years and 49.4% were male. The mean midazolam dose was 1.9 mg. 16.2% of patients had a low dose of midazolam (<2 mg of midazolam), 74.5% a standard dose of midazolam (2 mg), and 9.3% a high dose (>2 mg). In the low dose cohort, the polyp detection rate (PDR) was 20.8%, in the standard dose, PDR was 26.9% and in the high dose PDR was 16.4%. Rates of agitation were significantly higher in patients who received higher doses of midazolam. When patients with poor bowel preparation were removed from the cohort (n = 5534), PDR was 21.4% in the low dose cohort vs. 27.1% in the standard dose. View this table: Abstract PWE-043 Table 1 Conclusion Adequate sedation of patients during endoscopy is important for patient comfort. In this study we demonstrate that a standard dose of midazolam is associated with a higher polyp detection rate than lower doses. Midazolam has been previously demonstrated to inhibit peristalsis in animal studies by preventing release of 5-HT and this is a probable mechanism for our findings. Limitations arise from the retrospective nature of this study, however, even following stratification of patients by adequacy of bowel prep, PDR remained lower in the low dose midazolam group. Appropriate patient selection for standard dose midazolam is important to avoid respiratory and cardiovascular compromise. Further confirmatory prospective studies are warranted. Disclosure of Interest None Declared." @default.
• W2115131296 created "2016-06-24" @default.
• W2115131296 creator A5006842104 @default.
• W2115131296 creator A5043827885 @default.
• W2115131296 creator A5052565017 @default.
• W2115131296 creator A5064165126 @default.
• W2115131296 creator A5078541371 @default.
• W2115131296 date "2014-06-01" @default.
• W2115131296 modified "2023-09-27" @default.
• W2115131296 title "PWE-043 Polyp Detection Rate And Association With Midazolam Dose: Abstract PWE-043 Table 1" @default.
• W2115131296 doi "https://doi.org/10.1136/gutjnl-2014-307263.303" @default.
• W2115131296 hasPublicationYear "2014" @default.
• W2115131296 type Work @default.
• W2115131296 sameAs 2115131296 @default.
• W2115131296 citedByCount "0" @default.
• W2115131296 crossrefType "journal-article" @default.
• W2115131296 hasAuthorship W2115131296A5006842104 @default.
• W2115131296 hasAuthorship W2115131296A5043827885 @default.
• W2115131296 hasAuthorship W2115131296A5052565017 @default.
• W2115131296 hasAuthorship W2115131296A5064165126 @default.
• W2115131296 hasAuthorship W2115131296A5078541371 @default.
• W2115131296 hasBestOaLocation W21151312961 @default.
• W2115131296 hasConcept C121608353 @default.
• W2115131296 hasConcept C126322002 @default.
• W2115131296 hasConcept C167135981 @default.
• W2115131296 hasConcept C2776814716 @default.
• W2115131296 hasConcept C2778000748 @default.
• W2115131296 hasConcept C2778435480 @default.
• W2115131296 hasConcept C2778451229 @default.
• W2115131296 hasConcept C42219234 @default.
• W2115131296 hasConcept C526805850 @default.
• W2115131296 hasConcept C71924100 @default.
• W2115131296 hasConcept C72563966 @default.
• W2115131296 hasConcept C90924648 @default.
• W2115131296 hasConceptScore W2115131296C121608353 @default.
• W2115131296 hasConceptScore W2115131296C126322002 @default.
• W2115131296 hasConceptScore W2115131296C167135981 @default.
• W2115131296 hasConceptScore W2115131296C2776814716 @default.
• W2115131296 hasConceptScore W2115131296C2778000748 @default.
• W2115131296 hasConceptScore W2115131296C2778435480 @default.
• W2115131296 hasConceptScore W2115131296C2778451229 @default.
• W2115131296 hasConceptScore W2115131296C42219234 @default.
• W2115131296 hasConceptScore W2115131296C526805850 @default.
• W2115131296 hasConceptScore W2115131296C71924100 @default.
• W2115131296 hasConceptScore W2115131296C72563966 @default.
• W2115131296 hasConceptScore W2115131296C90924648 @default.
• W2115131296 hasIssue "Suppl 1" @default.
• W2115131296 hasLocation W21151312961 @default.
• W2115131296 hasLocation W21151312962 @default.
• W2115131296 hasOpenAccess W2115131296 @default.
• W2115131296 hasPrimaryLocation W21151312961 @default.
• W2115131296 hasRelatedWork W183937390 @default.
• W2115131296 hasRelatedWork W2056983530 @default.
• W2115131296 hasRelatedWork W2107370715 @default.
• W2115131296 hasRelatedWork W2134806986 @default.
• W2115131296 hasRelatedWork W2263160176 @default.
• W2115131296 hasRelatedWork W2316283096 @default.
• W2115131296 hasRelatedWork W2354736954 @default.
• W2115131296 hasRelatedWork W2409581964 @default.
• W2115131296 hasRelatedWork W2587610699 @default.
• W2115131296 hasRelatedWork W4323904173 @default.
• W2115131296 hasVolume "63" @default.
• W2115131296 isParatext "false" @default.
• W2115131296 isRetracted "false" @default.
• W2115131296 magId "2115131296" @default.
• W2115131296 workType "article" @default.